BioAdaptives, Inc. (OTC: BDPT) has announced the upcoming commercial launch of XcellaraHeart, a new cardiovascular wellness supplement that combines the company's Xcellara stem/progenitor cell mobilization formula with Tanshinone IIA, a bioactive compound derived from Danshen root. The product is scheduled to be available for order beginning Aug. 1, 2026, with initial deliveries expected in early August.
The Xcellara base formula is supported by a randomized, double-blind, placebo-controlled clinical trial that demonstrated an average 268.8% increase in circulating primitive stem/progenitor-type cells after four weeks, with zero adverse effects on more than twenty blood parameters. Tanshinone IIA has been studied for its effects on the SDF-1α/CXCR4 signaling pathway, which is associated with cellular trafficking and cardiovascular repair biology.
BioAdaptives said the product is designed around a two-part cardiovascular wellness strategy: stem/progenitor cell mobilization combined with cardiovascular signaling support. A scientific evidence dossier detailing the formulation is available on the company's product website at products.xcellara.com.
The Xcellara product line includes seven targeted formulas combining the clinically proven mobilization base with tissue-specific signaling ingredients for cardiac, joint, neural, dermal, longevity, and stress-resilience applications. The complete scientific evidence dossier for XcellaraHeart will be available at products.xcellara.com/science, separating what has been demonstrated in BioAdaptives' human clinical research on the Xcellara base from published research on Tanshinone IIA and the company's product-development rationale for combining the two.
BioAdaptives is the developer of the Xcellara line of stem cell mobilization and tissue-homing supplements. For more information, visit the company's website at www.bioadaptives.com.
